University of Kent Appoints Leading Cancer ResearcherNovember 15, 1999One of the UK¡¦s leading cancer researchers, Professor Bill Gullick, is to become the University of Kent at Canterbury¡¦s (UKC) new Chair in Cancer Biology from 1 January 2000. Currently Principal Scientist at the Imperial Cancer Research Fund (ICRF) Molecular Oncology Unit in Hammersmith, and Professor of Molecular Oncology at the Imperial College School of Medicine, he has recently been appointed President-Elect of the Federation of European Cancer Societies. In addition to bringing exciting new research programmes to UKC¡¦s already highly-rated Department of Biosciences, Professor Gullick will also foster links with the University¡¦s Kent Institute of Medical Health Studies (KIMHS) and the local NHS Trust in order to further develop cancer studies in the South East and particularly East Kent. Professor Gullick has a range of research interests in the cancer field including: „h the role of growth factors (particularly epidermal growth factor, EGF) in human breast and colon cancer „h the development of surrogate marker systems that can be used in preclinical models of drug evaluation and potentially in patients to optimise drug dosing and scheduling „h the use of advanced cell imaging technologies to monitor the cellular distribution of growth factors and their receptors in normal and cancer cells Professor Gullick publishes his research widely in leading international cancer and cell biology journals. He is a Fellow of the Royal College of Pathologists, a member of a number of learned societies and seven different journal editorial boards including the British Journal of Cancer. Ends Kent, University of |
|||||||||||||||||||||
| Related Cancer Current Events and Cancer News Articles U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. SNM applauds House action to build medical isotopes reactor in the US SNM applauds the U.S. House of Representatives for its passage of H.R. 3276-the American Medical Isotopes Production Act of 2009. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. New finding suggests prostate biopsy is not always necessary Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy. PET imaging response a prognostic factor after thoracic radiation therapy for lung cancer A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting. Scientists visualize how bacteria talk to one another Using imaging mass spectrometry, researchers at the University of California, San Diego have developed tools that will enable scientists to visualize how different cell populations of cells communicate. Findings show nanomedicine promising for treating spinal cord injuries Researchers at Purdue University have discovered a new approach for repairing damaged nerve fibers in spinal cord injuries using nano-spheres that could be injected into the blood shortly after an accident. Scientists uncover new key to the puzzle of hormone therapy and breast cancer The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. Breast density associated with increased risk of cancer recurrence A new study finds that women treated for breast cancer are at higher risk of cancer recurrence if they have dense breasts. Published in the December 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study's results indicate that breast cancer patients with dense breasts may benefit from additional therapies following surgery, such as radiation. More Cancer Current Events and Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||